Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pancreatic Ductal Adenocarcinoma: early-phase trial registry
56 of 85 indexed Pancreatic Ductal Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #165 of 28,707 conditions by registered trial count.
85 US clinical trials · 56 currently recruiting · #165 of 28,707 conditions by registered trial count
Pancreatic Ductal Adenocarcinoma: 85 US clinical trials tracked, 56 recruiting.
Pancreatic Ductal Adenocarcinoma is the subject of 85 registered US clinical trials on ClinicalTrials.gov, 56 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 68 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 5 of these trials.
Enrollment posture brief
Registry condition pancreatic-ductal-adenocarcinoma
OPEN 56 | RECR 66% | LATE 1 | EARLY 68 | RANK #165 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Solid Tumor, Adult (66% recruiting · 73 trials)
Pancreatic Ductal Adenocarcinoma lists 56 open slots (66% of 85 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pancreatic Ductal Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pancreatic Ductal Adenocarcinoma is recruiting above its size-band peers.
56 of 85 indexed trials (65.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Pancreatic Ductal Adenocarcinoma trials is spread across many organizations.
AstraZeneca accounts for 5 of 85 trials (5.9%). 64 distinct sponsors appear on at least one study for this condition label.
-
Typical Pancreatic Ductal Adenocarcinoma enrolment sits around 100 participants.
Median target enrolment is 100 among the 85 trials that report a genuine target (sentinel values excluded). 41 of those (48.2%) plan for fewer than 100 participants.
-
Pancreatic Ductal Adenocarcinoma research is mostly interventional.
72 interventional and 13 observational studies make up this index (84.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
85 total, page 2 of 2
Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma
The University of Texas Health Science Center, Houston
NCT06831136
A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
University of Rochester
NCT04477343
PHL Treatment in Pancreatic Cancer
Fox Chase Cancer Center
NCT05365893
Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer
Rutgers, The State University of New Jersey
NCT05296421
Fecal Microbial Transplants for the Treatment of Pancreatic Cancer
M.D. Anderson Cancer Center
NCT04975217
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
Radiopharm Theranostics
NCT05799274
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
NCT06607185
A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma
Memorial Sloan Kettering Cancer Center
NCT01983410
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
NCT05692596
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
AbbVie
NCT06084481
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines
NCT05462717
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals
NCT04913337
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
Elicio Therapeutics
NCT05726864
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
National Cancer Institute (NCI)
NCT02498613
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
Genentech
NCT05867121
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
Affini-T Therapeutics
NCT06105021
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT05983133
A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer
Boehringer Ingelheim
NCT05846516
GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT00878163
A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma
Thomas Jefferson University
NCT04111172
Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma
HonorHealth Research Institute
NCT03915444
Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
NCT05141643
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
NCT06168812
Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)
University of Kansas Medical Center
NCT05915351
A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma
Andrew Hendifar, MD
NCT05336266
AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC
Bruno Bockorny
NCT05632328
Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception Center
H. Lee Moffitt Cancer Center and Research Institute
NCT06712797
Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer
Duke University
NCT05634720
Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
NCT00669734
Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma
Case Comprehensive Cancer Center
NCT05209074
ZN-c3 + Gemcitabine in Pancreatic Cancer
Brandon Huffman, MD
NCT06015659
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
Alliance for Clinical Trials in Oncology
NCT06115499
Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer
Ambry Genetics
NCT02790944
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Incyte Corporation
NCT04580485
CT Pancreas Perfusion
Mayo Clinic
NCT00588367
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 47 |
| Phase 2 | 21 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Pancreatic Ductal Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pancreatic Ductal Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pancreatic Ductal Adenocarcinoma page
85 registered trials, 56 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 56 Pancreatic Ductal Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most Pancreatic Ductal Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pancreatic Ductal Adenocarcinoma condition card totals 85 registered trials; most-linked intervention Gemcitabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.